Compare ACEL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | VIR |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.7M | 1.0B |
| IPO Year | N/A | 2019 |
| Metric | ACEL | VIR |
|---|---|---|
| Price | $11.04 | $7.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.00 | ★ $28.63 |
| AVG Volume (30 Days) | 367.3K | ★ 1.9M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $1,307,029,000.00 | $16,860,000.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | $22.15 | ★ N/A |
| Revenue Growth | ★ 7.97 | N/A |
| 52 Week Low | $9.02 | $4.16 |
| 52 Week High | $13.28 | $10.67 |
| Indicator | ACEL | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 62.52 |
| Support Level | $11.07 | $7.25 |
| Resistance Level | $11.54 | $7.89 |
| Average True Range (ATR) | 0.27 | 0.51 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 15.38 | 85.10 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.